# US 2022/0031665 A1 · Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) nano-formulation of compounds and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031665 A1
- Document ID: US20220031665A1
- Status: Published application
- Kind: A1
- Application number: 17/276,543
- Filed: 2019-11-05
- Published: 2022-02-03
- Earliest claimed: 2018-11-05
- Assignees: Shifa Biomedical Corporation
- Applicants: Shifa Biomedical Corporation
- Inventors: Shaker A. Mousa; Nabil A. Elshourbagy; Harold V. Meyers; Sherin Salaheldin Abdel-Meguid
- Web page: https://patentgrep.com/patent/US20220031665A1

## CPC

- A61K 31/422: not condensed and containing further heterocyclic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 3/06: Antihyperlipidemics
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are Nanoformulated compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL- and related cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

## Claims

### Claim at position 1

1: A nanoparticle comprising at least one PCSK9 antagonist encapsulated within the nanoparticle, wherein said PCSK9 antagonist is a compound of Formula (I):
including pharmaceutically acceptable salts and stereoisomers of said compound,
wherein R1 is H or CH3; R2 and R3 are independently selected from the group consisting of H, halogen, (C1-C3)-alkyl and (C1-C3)-alkoxy; and R4 is selected from the group consisting of CO2R5, CONR5R6, aryl, and heteroaryl, wherein R5 and R6 are independently selected from the group consisting of H and (C1-C3)-alkyl.

### Claim at position 2 (depends on 1)

2: The nanoparticle of claim 1, wherein R4 is an aryl or heteroaryl.

### Claim at position 3 (depends on 2)

3: The nanoparticle of claim 2, wherein R4 is selected from the group consisting of 2-oxazole, 2-oxazoline, 2-benzoxazole and 2-benzimidazole.

### Claim at position 4 (depends on 1)

4: The nanoparticle of claim 1, wherein said PCSK9 antagonist is a compound of Formula (II):
including pharmaceutically acceptable salts and stereoisomers of said compounds,
wherein R1 is H or CH3; R2 is H or methoxy; R3 is H or halogen; and R7 is independently selected from the group consisting of H and (C1-C2)-alkyl or R7 are taken together to form an optionally substituted 6-membered carbocycle.

### Claim at position 5 (depends on 4)

5: The nanoparticle of claim 4, wherein if R1 is H, then R2 is H, and if R1 is methyl then R2 is methoxy.

### Claim at position 6 (depends on 4)

6: The nanoparticle of claim 4, wherein R7 are taken together to form an aryl.

### Claim at position 7 (depends on 1)

7: The nanoparticle of claim 1, wherein said halogen is fluorine.

### Claim at position 8 (depends on 1)

8: The nanoparticle of claim 1, wherein said PCSK9 antagonist is selected from the group consisting of SBC-115,418, SBC-115,433, SBC-115,448, SBC-115,462 and SBC-115,477.

### Claim at position 9 (depends on 1)

9: The nanoparticle of claim 1, wherein said PCSK9 antagonist is SBC-115,418.

### Claim at position 10 (depends on 1)

10: The nanoparticle of claim 1, wherein said nanoparticles are hydrophobic.

### Claim at position 11 (depends on 1)

11: The nanoparticle of claim 1, wherein said nanoparticles are chitosan hybrid nanoparticles, amine-modified poly-(lactic-co-glycolic acid) (PLGA) nanoparticles, solid lipid nanoparticles (SLNs), polyvinyl pyrrolidone (PVP) nanoparticles, hydroxypropyl methylcellulose acetate succinate (HPMC-AS) nanoparticles, or combinations thereof.

### Claim at position 12 (depends on 11)

12: The nanoparticle of claim 11, wherein said nanoparticles comprise chitosan and poly-(lactic-co-glycolic acid) (PLGA).

### Claim at position 13 (depends on 11)

13: The nanoparticle of claim 11, wherein said nanoparticles comprise polyvinyl pyrrolidone (PVP) and hydroxypropyl methylcellulose acetate succinate (HPMC-AS).

### Claim at position 14 (depends on 11)

14: The nanoparticle of claim 11, wherein said nanoparticles comprise polyvinyl pyrrolidone (PVP) and chitosan.

### Claim at position 15 (depends on 1)

15: The nanoparticle of claim 1, wherein said nanoparticle comprises a liver targeting moiety on the exterior of the nanoparticle.

### Claim at position 16 (depends on 15)

16: The nanoparticle of claim 15, wherein said liver targeting moiety is selected from the group consisting of Glycyrrhetinic acid (GA), Lactobionic acid (LA), Alginic acid and combinations thereof.

### Claim at position 17 (depends on 11)

17: The nanoparticle of claim 11, wherein said chitosan hybrid nanoparticle is selected from the group consisting of chitosan cross-linked to fatty acids, chitosan cross-linked to amino acids, chitosan cross-linked to hyaluronic acid, chitosan cross-linked to deoxycholic acid, chitosan cross-linked to Alginic acid, chitosan cross-linked to PLGA, and chitosan cross-linked to collagen-hydroxyapatite.

### Claim at position 18 (depends on 17)

18: The nanoparticle of claim 17, wherein said fatty acids are selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), DHA and EPA, linoleic acid, and combinations thereof.

### Claim at position 19 (depends on 17)

19: The nanoparticle of claim 17, wherein said amino acids comprise arginine.

### Claim at position 20 (depends on 1)

20: The nanoparticle of claim 1, wherein said nanoparticle further encapsulates at least one other LDL-lowering substance.

### Claim at position 21 (depends on 20)

21: The nanoparticle of claim 20, wherein said LDL-lowering substance is an anti-dyslipidemia agent.

### Claim at position 22 (depends on 21)

22: The nanoparticle of claim 21, wherein said anti-dyslipidemia agent is a statin, ezetimibe, bempedoic acid, a thyroid hormone receptor beta agonist, or a combination thereof.

### Claim at position 23 (depends on 1)

23: A composition comprising a nanoparticle of claim 1 and a physiologically compatible carrier medium.

### Claim at position 24 (depends on 1)

24: A method for delivering a PCSK9 antagonist to the liver of a subject, said method comprising administering at least one nanoparticle claim 1 to said subject.

### Claim at position 25 (depends on 24)

25: The method of claim 24, wherein said subject is human.

### Claim at position 26 (depends on 24)

26: The methods of claim 24, wherein said nanoparticle is administered to said subject in a composition further comprising a physiologically compatible carrier medium.

### Claim at position 27 (depends on 1)

27: A method for lowering serum cholesterol, LDL-C, and/or triglycerides and/or regulating other lipids biomarkers such as free cholesterol, cholesterol ester, HDL-C in a subject, said method comprising administering at least one nanoparticle of claim 1 to said subject.

### Claim at position 28 (depends on 27)

28: The method of claim 27, wherein said subject is human.

### Claim at position 29 (depends on 27)

29: The methods of claim 27, wherein said nanoparticle is administered to said subject in a composition further comprising a physiologically compatible carrier medium.

### Claim at position 30 (depends on 27)

30: The method of claim 27, wherein said subject has a disorder selected from the group consisting of dyslipidemia, atherosclerosis, cardiovascular disease, hypercholesterolemia, familial hypercholesterolemia, obesity, metabolic syndrome, type 2 diabetes, abdominal aortic aneurysms and combinations thereof.

### Claim at position 31 (depends on 27)

31: The method of claim 27, wherein the lowering of serum cholesterol, triglycerides, and/or lipid profile in the subject is sufficient to reduce the subject's cardiovascular risk.

### Claim at position 32 (depends on 1)

32: A method for treating or preventing hypercholesterolemia, and/or at least one symptom of dyslipidemia, atherosclerosis, CVD or coronary heart disease in a patient in need of said treatment, the method comprising administering to said patient a therapeutically effective amount of at least one nanoparticle of claim 1.

### Claim at position 33 (depends on 32)

33: The methods of claim 32, wherein said nanoparticle is administered to said subject in a composition further comprising a physiologically compatible carrier medium.

### Claim at position 34 (depends on 24)

34: The method of claim 24, further comprising the administration of at least one other LDL-lowering substance.

### Claim at position 35 (depends on 34)

35: The method of claim 34, wherein said LDL-lowering substance is an anti-dyslipidemia agent.

### Claim at position 36 (depends on 35)

36: The method of claim 35, wherein said anti-dyslipidemia agent is a statin, ezetimibe, bempedoic acid, a thyroid hormone receptor beta agonist, or a combination thereof.

### Claim at position 37

37: Nanoformulation comprising a combination of PVP/HPMC-AS/SBC-115,418 or analogues thereof and a liver targeting moiety.

### Claim at position 38 (depends on 37)

38: The nanoformulation of claim 37 wherein said liver targeting moiety is selected from the group consisting of Glycyrrhetinic acid (GA), Lactobionic acid (LA), Alginic acid or combinations thereof.

### Claim at position 39

39: A compound selected from the group consisting of SBC-115,433, SBC-115,448, SBC-115,462 and SBC-115,477.

### Claim at position 40 (depends on 39)

40: The compound of claim 39 selected from the group consisting of SBC-115,448, SBC-115,462 and SBC-115,477.

### Claim at position 41 (depends on 39)

41: The compound of claim 39 which is SBC-115,477.
